DBV Technologies stock threatens its €2 support level, under selling pressure
The biotech company specializing in immunotherapy against food allergies is among the strongest declines in the SBF 120 this Tuesday, in a nearly stable Paris index. The stock is approaching a closely monitored technical threshold, while declared short positions continue to increase.
A stock under pressure approaching dangerously close to the €2.00 support level
DBV Technologies is down 1.74% to €2.04 in trading, in an SBF 120 that is barely moving (-0.08%). The stock ranks among the index's strongest declines, intensifying a monthly decline of 14.24% and a three-month pullback of 29.16%. The €2.00 support is now less than half a point away from the current price, representing a gap of less than 2%: this level had previously acted as a floor during previous selling phases.
The RSI at 40 remains in neutral territory but declining, consistent with a gradual sliding dynamic rather than immediate selling exhaustion. Above the price, the three moving averages form a uniform ceiling: the 20-day MA at €2.20, the 50-day MA at €2.34 and the 200-day MA at €3.11, representing respective gaps of 7.45%, 12.99% and 34.53% above the current price, illustrating the extent of technical deterioration accumulated over several months.
Net short positions surge by nearly one point in thirty days
On the fundamentals side, DBV Technologies remains a company with no commercial revenues, whose cash position was presented, upon publication of first-half 2026 results on July 16, as sufficient to finance operations through the third quarter of 2027. The company was then engaged in regulatory discussions with the FDA, with a BLA filing submission anticipated for the third quarter of 2026. On the market, analyst opinions remain a central monitoring point for a security of this size.
Furthermore, according to recorded declarations, cumulative net short positions reach 4.30% of the capital, distributed among four funds, compared to 3.39% thirty days ago, representing a progression of 0.91 points in one month. This level, above the 3% threshold generally considered high for an SBF 120 security, reflects intensifying institutional downward pressure. This positioning says nothing about the exact motives of the funds concerned (hedging, directional bet), but its recent acceleration warrants consideration alongside the pressure being exerted on the €2.00 support, whose holding will determine the next price configuration.
